A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
This study is testing a new experimental medicine called TYRA-430 for people with advanced liver cancer or other solid tumors. The goal is to see if this medicine can effectively treat cancers that have specific genetic changes in the FGFR pathway, which helps fuel tumor growth.
You may be eligible if you are at least 18 years old and have an advanced cancer with specific genetic markers. You must also be able to perform your daily activities, swallow pills, and have generally healthy organ function.
Participants will take the experimental drug by mouth as doctors monitor their health, safety, and how well the body handles the medicine. The research team will track your progress closely to see if the treatment helps slow or shrink the tumor.
The study is currently recruiting patients at medical centers in Los Angeles, San Francisco, and Stanford, California. It is a first-in-human study, meaning it is the first time this specific drug is being tested in people.
- 1This is a Phase 1 study, the first step in testing a new treatment in humans.
- 2The drug is designed to target specific genetic mutations that help cancer grow.
- 3Participants will receive close medical supervision throughout the duration of the trial.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.